Treatment of bleeding with low half-life fibrinogen
US9962431B2 · kind B2 · utility
0Cited by
6References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2015 |
| Grant date | May 8, 2018 |
| Priority date | — |
| Expiry date | Dec 29, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition of recombinant human fibrinogen having a half-life of less than 12 hours and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition may also contain factor VIIa, factor VIII, von Willebrand's factor, or Desmopressin. The pharmaceutical composition may also contain divalent metal cations. The recombinant human fibrinogen may contain sialic acid.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.